Drug
Mexidol
Mexidol is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
67%(4 trials)
Phase Distribution
Ph phase_2
1
17%
Ph phase_3
3
50%
Ph phase_4
2
33%
Phase Distribution
0
Early Stage
1
Mid Stage
5
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
2(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(6)
Detailed Status
Completed6
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (16.7%)
Phase 33 (50.0%)
Phase 42 (33.3%)
Trials by Status
completed6100%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_2
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
NCT06903156
completedphase_4
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
NCT06437639
completedphase_3
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
NCT06834490
completedphase_3
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
NCT06854601
completedphase_4
MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure
NCT06221826
Clinical Trials (6)
Showing 6 of 6 trials
NCT06903156Phase 2
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
NCT06437639Phase 4
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
NCT06834490Phase 3
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
NCT06854601Phase 3
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
NCT06221826Phase 4
MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure
NCT02793687Phase 3
Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6